Navigation Links
Keryx Biopharmaceuticals to Present at William Blair & Company Small-Cap Growth Stock Conference
Date:10/1/2007

NEW YORK, Oct. 1 /PRNewswire-FirstCall/ -- Keryx Biopharmaceuticals, Inc. (Nasdaq: KERX) today announced that I. Craig Henderson, MD, the Company's President, will present an overview of the Company's cancer pipeline at the upcoming William Blair & Company Small-Cap Growth Stock Conference in New York City. Dr. Henderson's presentation will take place on Wednesday, October 3rd at 12:30 pm ET.

Dr. Henderson's presentation will be webcast live and will be accessible from the Investor Information page of the Company's Website at http://investors.keryx.com. An archived version of the webcast will be available following the conclusion of the live presentation.

ABOUT KERYX BIOPHARMACEUTICALS, INC.

Keryx Biopharmaceuticals, Inc. is focused on the acquisition, development and commercialization of medically important, novel pharmaceutical products for the treatment of life-threatening diseases, including diabetes and cancer. Keryx's lead compound under development is Sulonex(TM) (sulodexide), previously referred to as KRX-101, a first-in-class, oral heparinoid compound for the treatment of diabetic nephropathy, a life-threatening kidney disease caused by diabetes. Sulonex is in a pivotal Phase III and Phase IV clinical program under a Special Protocol Assessment with the Food & Drug Administration. Additionally, Keryx is developing Zerenex(TM), an oral, iron- based compound that has the capacity to bind phosphate and form non-absorbable complexes. Zerenex is currently in Phase II clinical development for the treatment of hyperphosphatemia (elevated serum phosphorous levels) in patients with end-stage renal disease. Keryx is also developing clinical-stage oncology compounds, including KRX-0401 (perifosine), a novel, first-in-class, oral modulator of Akt, a pathway associated with tumor survival and growth, and other important signal transduction pathways. KRX- 0401 is currently in Phase II clinical development for multiple tumor types. Keryx also has an active in- licensing and acquisition program designed to identify and acquire additional drug candidates. Keryx is headquartered in New York City.

KERYX CONTACT:

Lauren Fischer

Director - Investor Relations

Keryx Biopharmaceuticals, Inc.

Tel: 212.531.5965


'/>"/>
SOURCE Keryx Biopharmaceuticals, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Related medicine technology :

1. Keryx Biopharmaceuticals, Inc. Announces Positive Phase I and Phase II Data on KRX-0401 in Patients with Relapsed/Refractory Multiple Myeloma and Waldenstroms Macroglobulinemia
2. Keryx Biopharmaceuticals, Inc. Announces Poster Presentations Highlighting Mechanism of Action and Clinical Activity of Sulonex(TM) (sulodexide oral gelcap) at the Upcoming American Diabetes Association 67th Scientific Sessions in Chicago, Illinois
3. AEterna Zentaris Partner Keryx Presents Phase 1 and Phase 2 Results for Anti-Cancer Compound Perifosine at ASCO Meeting
4. Inspiration Biopharmaceuticals Presents Data From Hemophilia Program at International Society On Thrombosis and Haemostasis (ISTH) Annual Meeting
5. Accentia Biopharmaceuticals Announces Favorable Interim Blinded Data on SinuNase in Its Fast-Tracked Pivotal Phase 3 Clinical Trial for Chronic Sinusitis
6. Accentia Biopharmaceuticals Scientific Presentations Demonstrate Increasing Acceptance of Fungal Etiology of Chronic Sinusitis at the Annual Meeting of the American Academy of Allergy, Asthma, and Immunology
7. The Past, Present and Future of HLA Typing
8. Sygnis Pharma AG announces date for presentation of clinical results
9. Phase 3 Results for Dabigatran Etexilate, an Investigational Oral Anticoagulant, Presented Today at the XXIst Congress of the International Society on Thrombosis and Haemostasis
10. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
11. Halozyme Therapeutics Enhanze Technology Large Protein Molecule Therapeutic Clinical Trial Results Presented at the 34th Annual Meeting of the Controlled Release Society
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/21/2017)... , July 21, 2017  Endo International plc ... completing a comprehensive review of its manufacturing network, the ... and distribution facilities in Huntsville, Alabama ... take place over the next 12 to 18 months. ... impacted by declining volumes of commoditized products and these ...
(Date:7/15/2017)... 2017 Enterin Inc., a Philadelphia ... (PD), today announced the completion of a $12.7 million Series ... III, as well as the participation of existing investors. ... have the support of New Ventures III and our current ... of the potential of our platform technology to transform the ...
(Date:7/13/2017)... -- New York City-based market research firm Kalorama Information notes seven ... From new products to new costs, to the threat of ... study, Potential Pipeline Disruptors . Among them ... 1.  Age-Driven Growth - True Impact Moment Arriving   ... the growing population and, to a more extreme extent, the ...
Breaking Medicine Technology:
(Date:7/21/2017)... ... ... The Margarian Law Firm has filed a class action lawsuit against Dr. ... ginger. Dr. Pepper produces the “Canada Dry” brand of ginger ale products. In Gegham ... Ale claims on its bottle that it is made from real ginger. , When ...
(Date:7/21/2017)... ... July 21, 2017 , ... The Visiting ... the C. R. Bard Foundation, Inc. to support the music therapy ... service available through the nonprofit home care agency. Using evidence-based methods, professionally trained ...
(Date:7/21/2017)... ... July 21, 2017 , ... “Kids aren't born knowing how to regulate ... says Suzanne Tucker, Founder of St. Louis-based positive education company Generation Mindful. To help ... on Monday, July 21st. , The kit uses colorful, engaging and educational illustrations ...
(Date:7/21/2017)... ... July 21, 2017 , ... West Dermatology is pleased to announce ... Beginning July 17, 2017, Ms. Vu will join West Dermatology’s large network of medical ... dermatology, skin cancer , and more. She graduated from the University of Florida ...
(Date:7/21/2017)... ... July 21, 2017 , ... The most ... patients improved quality of life five years after injury, according to research presented ... in Toronto, Ontario, Canada. The study followed patients for five years following surgery. ...
Breaking Medicine News(10 mins):